HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First US Warnings On Drug Claims By Delta-8 THC Supplements Also Describe Safety Concerns

Executive Summary

Announcement and warnings, in addition to noting firms’ violative drug and disease claims, explain differences between delta-8 THC and other hemp-derived cannabinoids intended for de-scheduling as controlled substances in 2018 farm bill.

You may also be interested in...



Still No Appetite At US FDA For CBD In Food

Three years after similar warnings to make same impression, FDA warns five firms about using in food or beverage products CBD, the cannabinoid most commonly found in US, and delta-8 THC, a subject of ongoing discussion over whether it qualifies as hemp. One firm also warned about CBD in sunscreen.

‘Rope Not Dope’ Still Convince Congress On Hemp?

Failing to maintain key non-intoxicating distinction for hemp could cost US market its future. FDA appointment of senior policy advisor for cannabis could change things.

If US Court Says Delta-8 Product Is Lawful And Trademark Valid, Will Federal Agencies Listen?

Recent 9th Circuit ruling upheld granting a firm preliminary injunction stopping competitor from using its trademarked brand for delta-8 THC products. Ruling generally runs counter to USPTO policy against accepting trademark registrations for hemp or cannabis products and specifically counters FDA stance delta-8 doesn’t meet definition of hemp under 2018 farm bill.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel